Novel Acylselenourea Derivatives: Dual Molecules with Anticancer and Radical Scavenging Activity

Astrain-Redín, Nora; Raza, Asif; Encı́o, Ignacio; Sharma, Arun; Plano, Daniel; Sanmartín, Carmen

doi:10.3390/antiox12071331

Cited by 5 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous works, our research group has synthesized different acylselenoureas using several aromatic or aliphatic amines, rendering compounds with potent antitumor activity [ 40 , 41 ]. To the best of our knowledge, this work represents the first attempt to exchange the positions of N and Se to evaluate the differences in their biological activity.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Seleno-Warfare against Cancer: Decoding Antitumor Activity of Novel Acylselenoureas and Se-Acylisoselenoureas

Angulo-Elizari,

Raza,

Encío

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Currently, cancer remains a global health problem. Despite the existence of several treatments, including chemotherapy, immunotherapy, and radiation therapy, the survival rate for most cancer patients, particularly those with metastasis, remains unsatisfactory. Thus, there is a continuous need to develop novel, effective therapies. In this work, 22 novel molecules containing selenium are reported, including seven Se-acylisoselenoureas synthesized from aliphatic carbodiimides as well as acylselenoureas with the same carbo- and heterocycles and aliphatic amines. After an initial screening at two doses (50 and 10 µM) in MDA-MB-231 (breast), HTB-54 (lung), DU-145 (prostate), and HCT-116 (colon) tumor cell lines, the ten most active compounds were identified. Additionally, these ten hits were also submitted to the DTP program of the NCI to study their cytotoxicity in a panel of 60 cancer cell lines. Compound 4 was identified as the most potent antiproliferative compound. The results obtained showed that compound 4 presented IC50 values lower than 10 µM in the cancer cell lines, although it was not the most selective one. Furthermore, compound 4 was found to inhibit cell growth and cause cell death by inducing apoptosis partially via ROS production. Overall, our results suggest that compound 4 could be a potential chemotherapeutic drug for different types of cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In this work, as a continuation of our previous research, a library of novel acylselenoureas was designed together with their Se-acylisoselenoureas analogs [ 40 , 41 ]. The reason to design both libraries of compounds is to evaluate the impact of the exchange on nitrogen (N) and Se atoms in the molecules.…”

Section: Introductionmentioning

confidence: 99%

Seleno-Warfare against Cancer: Decoding Antitumor Activity of Novel Acylselenoureas and Se-Acylisoselenoureas

Angulo-Elizari,

Raza,

Encío

et al. 2024

Pharmaceutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Apoptosis tests were conducted using the Muse Annexin V/7‐AAD and Caspase 3/7‐7‐AAD kit from EMD Millipore, Darmstadt, Germany, following the provided protocol as described in Astrain‐Redin et al. (2023). The cells were initially seeded in a 6‐well plate at a density of 1 × 10 5 cells/well.…”

Section: Methodsmentioning

confidence: 99%

Design, synthesis, and biological evaluation of novel quinoxaline aryl ethers as anticancer agents

Nakka,

Raza,

Chaitanya

et al. 2024

Chem Biol Drug Des

Self Cite

View full text Add to dashboard Cite

We designed and synthesized thirty novel quinoxaline aryl ethers as anticancer agents, and the structures of final compounds were confirmed with various analytical techniques like Mass, 1H NMR, 13C NMR, FTIR, and elemental analyses. The compounds were tested against three cancer cell lines: colon cancer (HCT‐116), breast cancer (MDA‐MB‐231), prostate cancer (DU‐145), and one normal cell line: human embryonic kidney cell line (HEK‐293). The obtained results indicate that two compounds, FQ and MQ, with IC50 values < 16 μM, were the most active compounds. Molecular docking studies revealed the binding of FQ and MQ molecules in the active site of the c‐Met kinase (PDB ID: 3F66, 1.40 Å). Furthermore, QikProp ADME prediction and the MDS analysis preserved those critical docking data of both compounds, FQ and MQ. Western blotting was used to confirm the impact of the compounds FQ and MQ on the inhibition of the c‐Met kinase receptor. The apoptosis assays were performed to investigate the mechanism of cell death for the most active compounds, FQ and MQ. The Annexin V/7‐AAD assay indicated apoptosis in MDA‐MB‐231 cells treated with FQ and MQ, with FQ (21.4%) showing a higher efficacy in killing MDA‐MB‐231 cells than MQ (14.25%). The Caspase 3/7 7‐AAD assay further supported these findings, revealing higher percentages of apoptotic cells for FQ‐treated MDA‐MB‐231 cells (41.8%). The results obtained from the apoptosis assay conclude that FQ exhibits better anticancer activity against MDA‐MB‐231 cells than MQ.

show abstract

“…New drugs that improve the efficacy of current antitumor therapies for breast cancer are urgently needed. Medicinal chemists play an important role in the discovery of anticancer agents through the design, optimization, and development of new chemical compounds [4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Repurposing Study of 4-Acyl-1-phenylaminocarbonyl-2-substituted-piperazine Derivatives as Potential Anticancer Agents—In Vitro Evaluation against Breast Cancer Cells

Guillén-Mancina,

García-Lozano,

Burgos-Morón

et al. 2023

IJMS

View full text Add to dashboard Cite

Breast cancer is the most common type of cancer in women. Although current treatments can increase patient survival, they are rarely curative when the disease is advanced (metastasis). Therefore, there is an urgent need to develop new cytotoxic drugs with a high selectivity toward cancer cells. Since repurposing approved drugs for cancer therapy has been a successful strategy in recent years, in this study, we screened a library of antiviral piperazine-derived compounds as anticancer agents. The compounds included a piperazine ring and aryl urea functions, which are privileged structures present in several anti-breast cancer drugs. The selective cytotoxic activity of a set of thirty-four 4-acyl-2-substituted piperazine urea derivatives against MCF7 breast cancer cells and MCF 10A normal breast cells was determined. Compounds 31, 32, 35, and 37 showed high selective anticancer activity against breast cancer cells and were also tested against another common type of cancer, non-small cell lung cancer (A549 lung cancer cells versus MRC-5 lung normal cells). Compounds 35 and 37 also showed selectivity against lung cancer cells. These results suggest that compounds 35 and 37 may be promising hit compounds for the development of new anticancer agents.

show abstract

Novel Acylselenourea Derivatives: Dual Molecules with Anticancer and Radical Scavenging Activity

Cited by 5 publications

References 48 publications

Seleno-Warfare against Cancer: Decoding Antitumor Activity of Novel Acylselenoureas and Se-Acylisoselenoureas

Seleno-Warfare against Cancer: Decoding Antitumor Activity of Novel Acylselenoureas and Se-Acylisoselenoureas

Design, synthesis, and biological evaluation of novel quinoxaline aryl ethers as anticancer agents

Repurposing Study of 4-Acyl-1-phenylaminocarbonyl-2-substituted-piperazine Derivatives as Potential Anticancer Agents—In Vitro Evaluation against Breast Cancer Cells

Contact Info

Product

Resources

About